Regional differences in the long-term effect of neonatal 6-hydroxydopa treatment on rat brain noradrenaline

Neuroteratology and Animal Modeling of Brain Disorders

Over the past 60 years, a large number of selective neurotoxins were discovered and developed, making it possible to animal-model a broad range of human neuropsychiatric and neurodevelopmental disorders. In this paper, we highlight those neurotoxins that are most commonly used as neuroteratologic agents, to either produce lifelong destruction of neurons of a particular phenotype, or a group of neurons linked by a specific class of transporter proteins (i.e., dopamine transporter) or body of receptors for a specific neurotransmitter (i.e., NMDA class of glutamate receptors). Actions of a range of neurotoxins are described: 6-hydroxydopamine (6-OHDA), 6-hydroxydopa, DSP-4, MPTP, methamphetamine, IgG-saporin, domoate, NMDA receptor antagonists, and valproate. Their neuroteratologic features are outlined, as well as those of nerve growth factor, epidermal growth factor, and that of stress. The value of each of these neurotoxins in animal modeling of human neurologic, neurodegenerative, and neuropsychiatric disorders is discussed in terms of the respective value as well as limitations of the derived animal model. Neuroteratologic agents have proven to be of immense importance for understanding how associated neural systems in human neural disorders may be better targeted by new therapeutic agents.

Perinatal Lesioning and Lifelong Effects of the Noradrenergic Neurotoxin 6-Hydroxydopa

6-hydroxydopa (6-OHDOPA) was synthesized with the expectation that it would be able to cross the blood-brain barrier to be enzymatically decarboxylated to 6-hydroxydopamine (6-OHDA), the newly discovered neurotoxin for noradrenergic and dopaminergic neurons. In part, 6-OHDOPA fulfilled these criteria. When administered experimentally to rodents, 6-OHDOPA destroyed peripheral sympathetic noradrenergic nerves and did exert neurotoxicity to noradrenergic nerves in brain-in large part, from its conversion to 6-OHDA. However, the efficacy of 6-OHDOPA was less than that of 6-OHDA; also, 6-OHDOPA was relatively selective for noradrenergic neurons; near-lethal doses of 6-OHDOPA were required to damage dopaminergic nerves; and ultimately, 6-OHDOPA was found to be an agonist at AMPA receptors, thus accounting for more non-specificity. Nevertheless, 6-OHDOPA was found to be a particularly valuable tool in uncovering processes and mechanisms associated with noradrenergic nerve regeneration and sprouting, particularly when administered to perinatal rodents. Also, 6-OHDOPA was a good tool for selective mapping of noradrenergic nerve tracts in brain, since dopaminergic tracts were unaffected and did not interfere with the histofluorescent methodology used for this purpose in the early 1970s. As an experimental research tool, 6-OHDOPA was valuable in a short time-window, but its utility is largely limited because of newer research technologies that provide better means today for nerve tract mapping, and for experimental approaches engaged toward study of processes and mechanisms attending nerve regeneration. AMPA actions of 6-OHDOPA have not been extensively studied, so this avenue may enliven use of 6-OHDOPA in the future.

Developmental neuropathology in DNT-studies—A sensitive tool for the detection and characterization of developmental neurotoxicants

Developmental neurotoxicity (DNT-) studies are the first reproduction toxicity studies for which an extended histopathological examination of developing structures is required by the current EPA and OECD guidelines. The morphological screening includes a macroscopic evaluation of the brain and nervous tissue, brain weight parameters, gross morphometry of the brain, neurohistological examinations and a quantitative analysis of major brain areas. This review is intended to give an overview about the needs according to guideline requirements, practical approaches for a successful developmental neuropathology and its preconditions and does include examples of background data on the value and functional meaning of morphological data. A selection of experimental data from literature is also presented in the light of their contribution for the understanding of important, neurodevelopmental disorders in humans.

Selective neurotoxins, chemical tools to probe the mind: the first thirty years and beyond

For centuries, starting with the advent of the microscope, cytotoxins have been known to non-selectively destroy nerves and other tissue cells. However, neurotoxins restricted in effect to one kind of neuron are an invention of the 20th century. One might reasonably trace the origins of this field to 1960 when the Nobel Laureates, R. Levi- Montalcini and S Cohen, showed that an antibody to nerve growth factor effectively prevented development of sympathetic nerves in the absence of overt changes in dorsal root ganglia and other neural and non-neural tissues. The year 1967 marks discovery of 6-hydroxydopamine, the first of dozens of chemically-selective neurotoxins. As stated by the physiologist W.B. Cannon, neural function can be deduced by denoting absence-deficits. A wealth of knowledge in neuroscience has been realized through use of neurotoxins. In the 21st century we foresee neurotoxins for virtually all neurochemically-identifiable or receptor-specific neurons, acting at/via functional proteins or characteristic DNA sites. These tools will provide us with a better means to probe the mind and thereby lead to a fuller understanding of the intricate roles of identifiable neuronal systems in integrative neuroscience.

Free radical mechanisms in schizophrenia and tardive dyskinesia

The present article discusses the distribution of free radical processes in the central nervous system (CNS). Specifically, we discuss the involvement of oxyradicals in the normal metabolism of catecholamine. We also review some proposals related to the possible importance of these compounds in the development of neuropsychiatric and movement disorders such as schizophrenia and neuroleptic-induced tardive dyskinesia (TD), respectively. Clinical studies have shown that antioxidant treatment can attenuate the movement abnormalities observed in TD. Further studies are necessary to evaluate the status of specific scavenging systems in these two disorders. The prophylactic use of antioxidants in patients who are treated with neuroleptics needs also to be considered.

Free radical mechanisms in the central nervous system: an overview

Free radicals are highly toxic compounds which can react with a number of molecules such as glycoproteins or amino acids. These reactions can lead to the denaturation of proteins, destabilization of cellular membrane and eventually, cell death. Free radicals have been recently implicated in the pathogenesis and clinical course of a number of neuropsychiatric disorders including aging of the central nervous system (CNS), schizophrenia, and the development of tardive dyskinesia during chronic use of neuroleptics. This paper provides an overview of the nature of free radicals and discusses briefly their participation in the toxicity associated with catecholamines in the CNS.

Parallel changes in brain flunitrazepam binding and density of noradrenergic innervation

The neonatal injection of neurotoxic compounds such as 6-hydroxydopa (6-OH-DOPA) and DSP 4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride) produces marked changes in the development of central noradrenergic neurons, i.e. permanent denervation of the cerebral cortex and hyperinnervation of the brain stem and the cerebellum. Adult animals treated at birth with both neurotoxins were used to study the binding of [3H]flunitrazepam (FNZ) to membranes isolated from these regions. The administration of both toxins produced a marked and similar increase in the number of FNZ binding sites in the cerebellum. In the brain stem, 6-OH-DOPA increased the density of these receptors much more than DSP 4 (33% vs. 13%), a difference similar to that observed between the effects of both compounds on brain stem NA. In the cerebral cortex, both compounds reduced the maximal number of FNZ binding sites. No changes were observed in the affinity of FNZ binding sites in the different structures. When adult rats treated at birth with 6-OH-DOPA received an injection of DSP 4 7 days later, the number of FNZ binding sites was reduced by 43% in the cerebellum, 53% in the brain stem and 11% in the cerebral cortex. In these structures, DSP 4 reduced the absolute number of FNZ binding sites to the same level both in rats treated at birth with 6-OH-DOPA and in non-treated animals receiving DSP 4 7 days before killing. These results are further support for the existence of close parallelism between the density of benzodiazepine receptors, as demonstrated by FNZ binding, and the density of brain noradrenergic innervation.

Substance P modifies the 6-hydroxydopamine induced alteration of postnatal development of central noradrenaline neurons

Systemic treatment of new-born rats with the catecholamine neurotoxin 6-hydroxydopamine leads to a permanent and selective alteration of the postnatal development of the central noradrenaline neurons, in particular of the locus coeruleus system. The changes involve a pronounced and permanent degeneration of distant nerve terminal projections (e.g. in the cerebral cortex and spinal cord) and a hyperinnervation of regions close to the noradrenaline perikarya (e.g. in the cerebellum and pons-medulla). Substance P administered intracisternally was found to counteract significantly both the 6-hydroxydopamine-induced denervation and hyperinnervation, as monitored by measuring endogenous noradrenaline levels and [3H]noradrenaline uptake in vitro. The counteracting effect of substance P disclosed a clear dose-response relationship and was most effective when injected on postnatal days one and two, while practically no effects were observed after injection on postnatal days three and four. Substance P treatment alone of new-born rats had no effect on the postnatal development of the regional monoamine levels. Binding studies employing radioligand technique showed substance P treatment to abolish the 6-hydroxydopamine-induced increase in beta-receptor binding in the frontal cortex, suggesting the 'spared' noradrenaline terminals to be functionally active. Substance P was shown to increase the utilization of noradrenaline in the neonatal stage. The results indicate that the counteracting effect of substance P may be due to a prevention of degeneration, growth stimulation and/or trophic influences on central noradrenaline neurons, possibly related to an excitatory effect of substance P on noradrenaline neurons.

Changes in the development of central noradrenaline neurons after neonatal axon lesions

The effects of early surgical lesions of ascending noradrenaline (NA) axons and 6-hydroxydopamine (6-OHDA) induced NA denervation of the spinal cord on the postnatal development of central NA neurons of the rat have been studied using histo- and neurochemical techniques. The lesions were performed during the first week after birth and analyzed at the age of one or two weeks or in the adult stage. Complete unilateral hemisection at the mesencephalic level in the neonatal stage produced marked reductions of the 3H-NA uptake in vitro in the cerebral cortex with concomitant significant increases (+30-50%) of the uptake on the ipsilateral side of the pons-medulla when determined in adulthood. Partial unilateral hemisection, restricted to produce an axotomy of the dorsal NA bundle, led to almost complete NA depletions in the cerebral cortex, while significant NA elevations were found in the mesencephalon (+25-40%), pons-medulla (+15%) and cerebellum (+90%) on the ipsilateral side. In the latter region a significant NA increase (+50%) was also observed in the controlateral side. Regional analysis of the 3H-NA uptake after partial hemisection gave similar results. Intraspinal injection of 6-OHDA on the day of birth resulted consistently in marked NA depletions (-90% or more) in the spinal cord, while the effects on NA in the cerebral cortex varied, being either unaffected or markedly reduced. Animals with unaffected cerebral cortex disclosed a significant NA increase in the pons-medulla only, whereas animals with cortical NA denervation displayed significant increases in endogenous NA levels both in the pons-medulla and the cerebellum. The present results give further support for the "pruning effect" concept explaining the growth response that central NA neurons exhibit after neonatal 6-OHDA treatment systemically or when one axonal branch is damaged neonatally.

Substance P counteracts neurotoxin damage on norepinephrine neurons in rat brain during ontogeny

Systemic treatment of newborn rats with the catecholamine neurotoxin 6-hydroxydopamine alters the postnatal development of the central norepinephrine neurons. The changes are permanent and consist of denervation of distant nerve terminal projections (for example, cerebral cortex) and hyperinnervation of terminal areas close to the cell bodies (for example, cerebellum). Intracisternal injection of substance P counteracted both of these alterations. The results indicate that substance P may prevent degeneration of damaged norepinephrine neurons during ontogeny or may have a regrowth stimulatory action on these cells. Substance P might prove of use in the prevention or reduction of other types of neurodegenerative disease.

Enhancement of sprouting and putative regeneration of central noradrenergic fibers by morphine

Treatment of newborn rats with 6-hydroxydopa (6-OHDOPA, 60 micrograms/g IP) increased the levels of norepinephrine in the adult cerebellum and hindbrain. Concurrent treatment with morphine sulfate (20 micrograms/g IP) potentiated the response to 6-OHDOPA in the cerebellum and pons-medulla. In addition, increased noradrenergic neurite density in 4 week cerebellar cortex (as observed with histofluorescent staining by glyoxylic acid) suggests that neonatal morphine increased the sprouting of noradrenergic neurons in the 6-OHDOPA treated rats.

DSP-4: a novel compound with neurotoxic effects on noradrenergic neurons of adult and developing rats

The pharmacological actions of the compound N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride (DSP-4) are compatible with a specific neurotoxic effect on both peripheral and central noradrenergic neurons. The systemic injection of DSP-4 to adult rats transiently alters sympathetic neurons in the periphery but in the central nervous system the compound determines a marked and prolonged reduction of noradrenaline (NA) levels in all brain regions studied. When DSP-4 was injected systemically to rats at birth in doses ranging from 6.25 to 100 micrograms/g, no changes were found in peripheral sympathetic neurons 40 days later. On the contrary, in the same conditions and in relation to the dose injected, there were marked and persistent changes in the levels of NA in different regions of the brain. In the cerebral cortex and the spinal cord, the neonatal injection of SDP-4 produced a marked and long-lasting depletion of NA levels, similar to that observed after injection of the compound to adult rats. These changes were accompanied by a moderate increase in brain stem NA and a marked elevation of the amine in the cerebellum. These changes, different from the depletion observed in both regions when the compound was given to adult rats, are however similar to those observed after the neonatal injection of the neurotoxic compounds 6-hydroxydopamine or its precursor amino acid, 6-hydroxydopa. This indicates that probably central noradrenergic neurons respond in the same manner after different chemical injuries. DSP-4 crosses the placental barrier because when it was given to pregnant rats at the end of gestation, long-term changes were found in brain NA levels in their offspring, similar to those produced by the neonatal administration of the compound. This new neurotoxic compound provides a very useful tool for the study of noradrenergic neurons both in adult animals and during ontogenesis.

Intraventricular 6-hydroxydopamine in the newborn rat and locomotor responses to drugs in infancy: no support for the dopamine depletion model of minimal brain dysfunction

Bilateral intraventricular injections of 6-hydroxydopamine (6-OHDA) after desmethylimipramine (DMI) in rats 1 and 2 days of age, severely depleted brain dopamine (DA) particularly in the neostriatum, where levels in adulthood were about 7% of control. Compared to vehicle-injected controls these rats were hyperactive only at 15 and 20 days of age, and in adulthood were impaired in a two-way avoidance. Rats with similar 6-OHDA treatment but without DMI pretreatment showed severe depletion of brain norepinephrine (NE) as well as DA, and were behaviorally similar to the DA-depleted only rats. This behavioral syndrome is similar to that reported after intracisternal injection of 6-OHDA in 5-day-old rats, which has been argued as a model for minimal brain dysfunction (MBD). Contrary to expectation from this model, however, challenge doses of either d-amphetamine or methylphenidate did not reduce, but instead increased activity of these rats. The 6-OHDA treatments also did not alter the enhancement of locomotor activity by scopolamine, which was present at 30 days but not at 15 days.

Effects of 6-hydroxydopamine and 6-hydroxydopa on development of behavior

Rats treated at birth with 6-hydroxydopamine (6-OHDA) (60 microgram/g, IP) or 6-hydroxydopa (6-OHDOPA X2) (60 microgram/g, IP at birth and 48 hr later) exhibited increases in general activity throughout the initial 5 weeks after birth, with peak activity occurring around 20 days postnatally. Activity changes in the 6-OHDOPAx2 group appeared to be due to increased exploratory behavior (ambulation, climbing, rearing, sniffing), while the 6-OHDA changes appeared to be due to the increased self-directed behavior (eating, grooming, scratching). Despite these behavioral differences there was no obvious difference between treated groups in norepinephrine (NE) levels in the various brain regions, i.e., all treatments resulted in a reduction in neocortical and hippocampal NE and an elevation in cerebellar NE. These findings suggest that noradrenergic neurons may be altered to different degrees by each agent in more discrete brain regions than were tested, or that other neurotransmitter systems may be more selectively altered by either of the drug treatments. Because striatal dopamine was unaltered in any of the groups, however, there is reason to question a previously suggested link between minimal brain dysfunction (MBD) and dopamine depletion in the neonatal brain.

Loss of nerve cell bodies in caudal locus coeruleus following treatment of neonates with 6-hydroxydopa

The locus coeruleus is a well defined nucleus in cresylechtviolet preparations and the perikarya are easily distinguished. The coeruleus neurons are thought to be noradrenergic and during development can be selectively affected by the neurotoxin, 6-hydroxydopa (6-OHDOPA). In 6-month-old rats that were treated on day of birth with 6-OHDOPA (60 mg/kg, i.p.) there was a 32% loss of nerve cell bodies in the locus coeruleus. While it was apparent that loss of cell bodies occurred throughout the entire nucleus, the greatest loss of perikarya was from the caudal extent of the nucleus. It is known that sprouting of noradrenergic terminals occurs in the cerebellum of rats following treatment of newborns with 6-OHDOPA. That there are fewer cell bodies to contribute additional terminals further dramatizes this sprouting phenomenon.

Morphological evidence for 6-hydroxydopamine-induced sprouting or noradrenergic neurons in the cerebellum

Intracisternal injection of 6-hydroxydopamine (6-OHDA) into young rats during the first 24 hours after birth resulted in a significant elevation of cerebellar norepinephrine by day 9. This elevation continued through 120 days. Fluorescence microscopy demonstrated an increased fluorescence in all layers of the cerebellar cortex in treated rats from 9 days after treatment through 120 days. This was considerably greater than the normal developmental change observed in control rats and appeared to be due to an increased number of fluorescent terminals. Quantitative electron-microscopic analysis indicated that all layers of the cerebellar cortex of treated rats contained significantly more boutons with small dense-cored vesicles (SGV), a morphologic marker for catecholamines, than controls. No significant difference in the number of SGVs per bouton was observed in 6-OHDA treated rats.

Apomorphine-induced locomotor stimulation in developing rats treated with 6-hydroxydopa

Apomorphine-induced locomotor stimulation was investigated in the developing rat following injection with 6-hydroxydopa at birth. Treatment with 6-hydroxydopa potentiated locomotor responsiveness to apomorphine in the 20-day-old rat. The 6-hydroxydopa-treated animal at 30 days, however, was less sensitive to the drug than was the control. Apomorphine again elicited more locomotor stimulation in 6-hydroxydopa-treated animals than in the controls on day 50. These results suggest that the altered sensitivity of dopamine receptors induced with 6-hydroxydopa, is influenced by the onset of activity of other "inhibitory" neurons on day 30.

A biochemical and morphological study of the altered growth pattern of central catecholamine neurons following 6-hydroxydopamine

In this study the effect of administering 6-hydroxydopamine (6-OHDA) intracisternally on brain catecholamine content and fluorescence patterns of cerebellar processes was examined. It was found that intracisternal injection of 6-OHDA resulted in widely diverging effects depending upon the dose of 6-OHDA, age of the animal upon injection and the length of the post injection interval. Small doses of 6-OHDA (3 and 10 microgram) selectively depleted telencephalic and upper brain stem NE while larger doses of 6-OHDA (30 and 100 microgram) infringed on dopaminergic as well as noradrenergic neurons. In addition, the lower doses of 6-OHDA, but not the higher ones, led to an approximately two-fold accumulation of NE in the lower brain stem and cerebellum. Morphological observations suggested that the cerebellar norepinephrine accumulation after 10 microgram 6-OHDA was attributable primarily to an invasion of noradrenergic processes into the cerebellum.

Differential effect of various 6-hydroxydopa treatments on the development of central and peripheral noradrenergic neurons

6-Hydroxydopamine or 6-hydroxydopa injected systemically into newborn rats produced marked changes in the development of central and peripheral noradrenergic neurons. Noradrenaline concentration was elevated in the brain stem, particularly in the pons, and decreased in the cerebral cortex and the spinal cord while in the cerebellum, the effects were dependent on the mode of administration. The changes produced by 6-hydroxydopa in brain regional noradrenaline were related to the dose injected at birth. Similar modifications in the development of central noradrenergic neurons were found in the offspring of rats which had received 6-hydroxydopa at 16 days of gestation. The involvement of peripheral sympathetic neurons varied with the compound used and the form of its administration. Thus, 6-hydroxydopamine produced a permanent although partial peripheral sympathectomy, an effect which was less evident following multiple injections of 6-hydroxydopa after birth and almost minimal after a single injection. The prenatal administration of 6-hydroxydopa did not alter peripheral sympathetic neurons. It is concluded that with the appropriate treatment schedule, it is possible to lesion selectively the noradrenergic neurons in the central nervous system.

Behavioral and biochemical effects of neonatal treatment of rats with 6-hydroxydopa

Rats receiving injection of either 6-hydroxydopa (60 mug/g) or saline on Days 1, 3, and 5 of life were studied in adulthood on a number of behavioral tasks before being sacrificed at 8 or 12 months for NE assay. The treated rats exhibited impaired passive avoidance, less shock-induced aggression, and more locomotor open-field activity than the control rats. There were no differences between the groups in male copulatory behavior, food and water intake, or thermoregulation. In comparison to the saline rats, 6-hydroxydopa rats showed elevated levels of endogenous NE in lower brainstem regions, e.g., midbrain and pons-medulla, as well as cerebellum. Hypothalamic NE level was not affected. Significant depletions of NE were obtained in the hippocampus and neocortex.

Exaggerated avoidance of novel stimulation in rats partially recovered from central norepinephrine damage

Rats in which central norepinephrine lesions are made with 6-OHDA and a recovery period allowed show a behavioral syndrome distinct from controls, from rats with more extensive norepinephrine damage (lesioned with 6-OHDA, allowed to recover, and relesioned), and from rats with general depletion of serotonin (chronic PCPA). These rats administered central 6-OHDA injections and then allowed a recovery period rear less in open field than all other groups and are characterized by an exaggerated avoidance of novel visual stimulation in light onset and light escape tests. It is proposed that this reflects the hyperresponsivity of partially repaired, supersensitive norepinephrine circuitry to novel or intense stimulation.

Early behavioral and catecholaminergic effects of 6-hydroxydopamine and guanethidine in the neonatal rat

New born rats received 7 consecutive daily injections of 6-hydroxydopamine (6-OHDA) or guanethidine. Locomotor activity, measured at 3 day intervals, was differentially affected by these drugs, although neither drug elimination a characteristic pattern of ontogeny of locomotor activity. Differing neurochemical effects were also observed. 6-OHDA decreased tyrosine hydroxylase activity in cortex and cerebellum, increased it in the brainstem and had no effect on the hypothalamus. Guanethidine slightly elevated enzyme levels in all four brain regions, with the elevation in brainstem significant at 16 days of age. Regional brain changes in enzyme activity after 4 daily 6-OHDA injections beginning at 1, 5 or 9 days of age indicated that toxic effect of 6-OHDA upon catecholaminergic neurons was age dependent. These data are not consistent with a simple interpretation either in terms of maturational changes in blood brain barrier permeability to 6-OHDA or neuronal uptake of the drug. Further analyses of brainstem areas indicated that the increased brainstem enzyme activity after 6-OHDA was restricted to the pons.

6-hydroxydopa during development of central adrenergic neurons produces different long-term changes in rat brain noradrenaline

6-hydroxydopa (6-OH-DOPA) administered to rats during their early development produces long-term modifications in the content of brain noradrenaline (NA) which have regional differences. An increase in brain stem NA is observed when the rats are exposed to the drug between the day 14 of gestation and the 9th postnatal day. When 6-OH-DOPA is injected subcutaneously on the 13th postnatal day or later, there is a decrease in brain stem NA. On the other hand, the content of NA in the telediencephalon is depleted for the first time in rats exposed to the drug during the day 16 of gestation, the decrease is more evident when the injection is done on days 17 or 18 and the effect is also marked when the drug is administered in the period between the day of birth and the 20th day of age. These results indicate that 6-OH-DOPA exerts different effects during the process of development and that the increase in brain stem NA is not solely dependent on the depletion produced in the forebrain because both phenomena are temporally dissociated. The adrenergic neurons injured by the drug, most probably respond in such a way that leads to an increase in brain stem NA only during the period in which they are under the influence of the factors controlling their physiologic development.